Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

LivaNova PLC (LIVN)

53.67   -0.05 (-0.09%) 11-25 13:00
Open: 53.49 Pre. Close: 53.72
High: 53.99 Low: 53.34
Volume: 76,569 Market Cap: 2,873(M)

Technical analysis

as of: 2022-11-25 1:58:31 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 64.72     One year: 75.59
Support: Support1: 48.85    Support2: 44.79
Resistance: Resistance1: 55.41    Resistance2: 64.72
Pivot: 51.46
Moving Average: MA(5): 53.34     MA(20): 50.46
MA(100): 55.2     MA(250): 67.07
MACD: MACD(12,26): 1.2     Signal(9): 0.8
Stochastic oscillator: %K(14,3): 79.8     %D(3): 81.6
RSI: RSI(14): 60.5
52-week: High: 89.69  Low: 41.81
Average Vol(K): 3-Month: 453 (K)  10-Days: 561 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ LIVN ] has closed below upper band by 21.7%. Bollinger Bands are 3.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 54.77 - 54.98 54.98 - 55.14
Low: 52.31 - 52.57 52.57 - 52.77
Close: 53.34 - 53.73 53.73 - 54.05

Company Description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Headline News

Mon, 21 Nov 2022
Notable Monday Option Activity: NBR, LIVN, RCL - Nasdaq

Mon, 21 Nov 2022
Add Up The Parts: MVV Could Be Worth $57 - Nasdaq

Fri, 18 Nov 2022
LivaNova LifeSparc ACS pump cleared for extended use - Mass Device

Mon, 07 Nov 2022
LivaNova PLC 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:LIVN) - Seeking Alpha

Mon, 07 Nov 2022
LivaNova PLC (LIVN) Q3 2022 Results - Earnings Call Transcript - Seeking Alpha

Sun, 06 Nov 2022
LivaNova (NASDAQ:LIVN) Stock Rating Upgraded by StockNews.com - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. 54 (M)
Shares Float 53 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 107.6 (%)
Shares Short 1,930 (K)
Shares Short P.Month 1,900 (K)

Stock Financials

EPS -1.98
EPS Est Next Qtl 0.8
EPS Est This Year 3.25
EPS Est Next Year 3.51
Book Value (p.s.) 21.43
Profit Margin (%) -9.2
Operating Margin (%) 13.3
Return on Assets (ttm) 3.8
Return on Equity (ttm) -7.6
Qtrly Rev. Growth -0.3
Gross Profit (p.s.) 13.03
Sales Per Share 19.05
EBITDA (p.s.) 3.42
Qtrly Earnings Growth 0
Operating Cash Flow 85 (M)
Levered Free Cash Flow -162 (M)

Stock Valuations

PE Ratio -27.25
PEG Ratio -5.1
Price to Book value 2.5
Price to Sales 2.81
Price to Cash Flow 33.91

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.